These therapies block the binding of hormone receptors to their corresponding receptors or decrease androgen-derived estrogen formation, which inhibit the proliferation of tumors and reduce the risk of tumor recurrence and metastasis [18–19]. Here, NR4A1 is linked to neoplasm.